NASDAQ: MRSN
Mersana Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for MRSN

Based on 2 analysts offering 12 month price targets for Mersana Therapeutics Inc

Min Forecast
$5.00+1,262.4%
Avg Forecast
$7.50+1,943.6%
Max Forecast
$10.00+2,624.8%

Should I buy or sell MRSN stock?

Based on 2 analysts offering ratings for Mersana Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MRSN stock forecasts and price targets.

MRSN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-05-16

1 of 1

Forecast return on equity

Is MRSN forecast to generate an efficient return?

Company
-52.49%
Industry
140.86%
Market
89.98%
MRSN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MRSN forecast to generate an efficient return on assets?

Company
14.41%
Industry
32.43%
MRSN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MRSN earnings per share forecast

What is MRSN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.51
Avg 3 year Forecast
-$0.64

MRSN revenue forecast

What is MRSN's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$22.2M-34.59%
Avg 2 year Forecast
$72.0M+111.58%
Avg 3 year Forecast
$20.5M-39.72%
MRSN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MRSN revenue growth forecast

How is MRSN forecast to perform vs Biotechnology companies and vs the US market?

Company
13.9%
Industry
56.37%
Market
9.57%
MRSN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MRSN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MRSN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MRSN$0.37$7.50+1,943.60%Strong Buy
CUE$0.60$2.00+232.23%Buy
ATNM$1.49$4.00+168.46%Buy
PEPG$1.43$5.50+284.62%Hold
ATHE$4.40$12.00+172.73%Strong Buy

Mersana Therapeutics Stock Forecast FAQ

Is Mersana Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MRSN) stock is to Strong Buy MRSN stock.

Out of 2 analysts, 2 (100%) are recommending MRSN as a Strong Buy, 0 (0%) are recommending MRSN as a Buy, 0 (0%) are recommending MRSN as a Hold, 0 (0%) are recommending MRSN as a Sell, and 0 (0%) are recommending MRSN as a Strong Sell.

If you're new to stock investing, here's how to buy Mersana Therapeutics stock.

What is MRSN's earnings growth forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Mersana Therapeutics's earnings in 2025 is -$74,009,000.On average, 5 Wall Street analysts forecast MRSN's earnings for 2025 to be -$74,031,015, with the lowest MRSN earnings forecast at -$99,705,071, and the highest MRSN earnings forecast at -$33,650,462. On average, 4 Wall Street analysts forecast MRSN's earnings for 2026 to be -$63,561,983, with the lowest MRSN earnings forecast at -$110,921,892, and the highest MRSN earnings forecast at -$16,202,074.

In 2027, MRSN is forecast to generate -$80,175,340 in earnings, with the lowest earnings forecast at -$110,921,892 and the highest earnings forecast at -$57,330,416.

What is MRSN's revenue growth forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of 13.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.

Mersana Therapeutics's revenue in 2025 is $34,006,000.On average, 5 Wall Street analysts forecast MRSN's revenue for 2025 to be $2,772,299,505, with the lowest MRSN revenue forecast at $342,736,182, and the highest MRSN revenue forecast at $4,337,170,597. On average, 4 Wall Street analysts forecast MRSN's revenue for 2026 to be $8,967,224,841, with the lowest MRSN revenue forecast at $2,492,626,780, and the highest MRSN revenue forecast at $24,926,267,800.

In 2027, MRSN is forecast to generate $2,554,942,450 in revenue, with the lowest revenue forecast at $1,994,101,424 and the highest revenue forecast at $3,115,783,475.

What is MRSN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MRSN) forecast ROA is 14.41%, which is lower than the forecast US Biotechnology industry average of 32.43%.

What is MRSN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MRSN price target, the average MRSN price target is $7.50, with the highest MRSN stock price forecast at $10.00 and the lowest MRSN stock price forecast at $5.00.

On average, Wall Street analysts predict that Mersana Therapeutics's share price could reach $7.50 by May 16, 2026. The average Mersana Therapeutics stock price prediction forecasts a potential upside of 1,943.6% from the current MRSN share price of $0.37.

What is MRSN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MRSN) Mersana Therapeutics's current Earnings Per Share (EPS) is -$0.59. On average, analysts forecast that MRSN's EPS will be -$0.59 for 2025, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.27. On average, analysts forecast that MRSN's EPS will be -$0.51 for 2026, with the lowest EPS forecast at -$0.89, and the highest EPS forecast at -$0.13. In 2027, MRSN's EPS is forecast to hit -$0.64 (min: -$0.89, max: -$0.46).

What is MRSN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MRSN) forecast ROE is -52.49%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.